|
|
|
|
| LEADER |
02203 am a22004933u 4500 |
| 001 |
92450 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Mascia, Salvatore
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemical Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemistry
|e contributor
|
| 100 |
1 |
0 |
|a Trout, Bernhardt L.
|e contributor
|
| 100 |
1 |
0 |
|a Mascia, Salvatore
|e contributor
|
| 100 |
1 |
0 |
|a Heider, Patrick L.
|e contributor
|
| 100 |
1 |
0 |
|a Zhang, Haitao
|e contributor
|
| 100 |
1 |
0 |
|a Lakerveld, Richard
|e contributor
|
| 100 |
1 |
0 |
|a Benyahia, Brahim
|e contributor
|
| 100 |
1 |
0 |
|a Barton, Paul I.
|e contributor
|
| 100 |
1 |
0 |
|a Braatz, Richard D.
|e contributor
|
| 100 |
1 |
0 |
|a Cooney, Charles L.
|e contributor
|
| 100 |
1 |
0 |
|a Evans, James M. B.
|e contributor
|
| 100 |
1 |
0 |
|a Jamison, Timothy F.
|e contributor
|
| 100 |
1 |
0 |
|a Jensen, Klavs F.
|e contributor
|
| 100 |
1 |
0 |
|a Myerson, Allan S.
|e contributor
|
| 100 |
1 |
0 |
|a Trout, Bernhardt L.
|e contributor
|
| 700 |
1 |
0 |
|a Heider, Patrick L.
|e author
|
| 700 |
1 |
0 |
|a Zhang, Haitao
|e author
|
| 700 |
1 |
0 |
|a Lakerveld, Richard
|e author
|
| 700 |
1 |
0 |
|a Benyahia, Brahim
|e author
|
| 700 |
1 |
0 |
|a Barton, Paul I.
|e author
|
| 700 |
1 |
0 |
|a Braatz, Richard D.
|e author
|
| 700 |
1 |
0 |
|a Cooney, Charles L.
|e author
|
| 700 |
1 |
0 |
|a Evans, James M. B.
|e author
|
| 700 |
1 |
0 |
|a Jamison, Timothy F.
|e author
|
| 700 |
1 |
0 |
|a Jensen, Klavs F.
|e author
|
| 700 |
1 |
0 |
|a Myerson, Allan S.
|e author
|
| 700 |
1 |
0 |
|a Trout, Bernhardt L.
|e author
|
| 245 |
0 |
0 |
|a End-to-End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation
|
| 260 |
|
|
|b Wiley Blackwell,
|c 2014-12-23T14:17:13Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/92450
|
| 520 |
|
|
|a A series of tubes: The continuous manufacture of a finished drug product starting from chemical intermediates is reported. The continuous pilot-scale plant used a novel route that incorporated many advantages of continuous-flow processes to produce active pharmaceutical ingredients and the drug product in one integrated system.
|
| 520 |
|
|
|a Novartis (Firm)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Angewandte Chemie International Edition
|
